Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Trial details
- Registry ID
- NCT07284459
- Drugs studied
- PIPE-791 Dose A, PIPE-791 Dose B
TrialRedline tracks 1 clinical trial sponsored by Contineum Therapeutics: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisNCT07284459 | PIPE-791 Dose A, PIPE-791 Dose B | Recruiting | 2028-05Estimated |
Names as written in the registry records.
NCT07284459 · Contineum Therapeutics
Before: Not yet recruiting. After: Recruiting.